Objectives. We conducted a casecontrol study to determine the association between KIR2D and KIR3D gene polymorphisms and their interaction with HLA alleles in PsA.
Introduction
Class I HLA alleles, particularly specific HLA-B and HLA-C alleles, are associated with psoriasis and PsA. The association between alleles of HLA class I molecules and PsA indicates a potential role for the innate immune system in PsA pathogenesis [14] . One important innate immune mechanism involving HLA class I recognition is through activation of natural killer (NK) and NK-T cells upon engagement of NK cell receptors, chiefly the killer cell Ig-like receptors (KIRs), encoded by a highly polygenic and polymorphic locus on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex [5] .
About 14 expressed KIR genes have been identified. The most commonly used nomenclature system accounts for their protein structure and consists of four major subdivisions based on two features: the number of extracellular Ig domains (2D or 3D) and characteristics of the cytoplasmic tail. Based on the length of the cytoplasmic domain, KIR receptors are classified as either long (L) or short (S). KIRs with long cytoplasmic domains are inhibitory by virtue of the immunoreceptor tyrosine-based inhibition motifs present in their cytoplasmic domains. Short-tailed KIRs transmit activating signals through their interaction with the adaptor molecule DAP-12 (DNAX activation protein of 12 kD), which contains immunoreceptor tyrosine-based activation motifs. Thus the following KIR gene polymorphisms have been described: KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DS1, KIR3DL3 and KIR2DL5. Two KIR pseudogenes (2DP and 3DP) have also been identified [6] .
NK cell function is regulated by a balance between positive-signalling receptors that initiate cell activation and inhibitory receptors that suppress it. NK cells are maintained in a quiescent state through the inhibitory KIRs. KIRs recognize the classical MHC class I HLA molecules. Specifically, KIR2D receptors recognize HLA-C ligands. HLA-C ligands are classified into two groups based on the presence of amino acid residues in certain positions of the a1 domain. This polymorphism is recognized by NK cells using different members of the KIR2D receptor. Thus the HLA-C molecules that have lysine at position 80 encoded by the HLA-C alleles *02, *04, *05, *06, *15, *1602, *17 and *18 (collectively termed HLA-C group 2) are recognized by KIR2DL1 (an inhibitory KIR) as well as, putatively, its corresponding activating KIR, KIR2DS1. On the other hand, the HLA-C molecules that have asparagine at position 80 encoded by the HLA-C alleles *01, *03, *07, *08, *12, *13, *14 and *1601 (collectively termed HLA-C group 1) are recognized by KIR2DL2/ L3 and putatively their corresponding activating KIR, KIR2DS2. The cell surface expression of HLA-C molecules is variable, with some alleles associated with higher expression. Studies in HIV indicate that high-expression HLA-C alleles (*02, *05, *06, *08, *12, *15 and *16) might confer better innate and/or acquired immune responses than low-expression HLA-C alleles [7, 8] .
HLA-B alleles may also be classified into Bw4 and Bw6 groups based on the amino acid positions 7983 of the HLA-B molecule [9] . The HLA-B Bw4 motif is present on HLA-B*1513, *1516, *1517, *1524, *2702, *3801, *4901, *51, *5201, *5301, *5302, *57, *58, *13, *3802, *44, *2705, *2709, *3701 and *4701 that have leucine and arginine at positions 82 and 83, respectively, whereas the HLA-B Bw6 motif is present on HLA-B*07, *0801, *14, *1501, *1503, *1504, *1507, *1509, *1515, *1518, *1522, *1537, *1538, *1545, *1548, *18, *35, *39, *40, *41, *42, *4501, *4601, *48, *50, *5401, *55, *56, *67, *7801, *8101, *8201 and *7301 that have asparagine, leucine, arginine and glycine at positions 8083, respectively. HLA-B Bw4 is further classified into Bw4 80ile and Bw4 80thr, based on the presence of the amino acid isoleucine or threonine at position 80. KIR3DL1 binds HLA-B Bw4, and HLA-B Bw4 molecules with Bw4 80ile may be better ligands than those with Bw4 80thr. KIR3DS1 may recognize at least some of the Bw4 allotypes [911] .
Independent segregation of HLA and KIR genes, along with KIR specificity for particular HLA allotypes, makes it possible that any given individual may express KIR molecules for which no ligand is present. The gene polymorphisms encoding inhibitory KIR2DL1, KIR2DL3 and KIR2DL4 receptors are detected in almost all individuals, whereas the activating receptor gene polymorphisms, KIR2DS1 and KIR2DS2, are detected in only 3556% of people of European ethnicity. Polymorphisms of the KIR gene complex and its interaction with HLA alleles may influence susceptibility to inflammatory diseases, viral infections and malignancies and pregnancy outcome [12] .
KIR gene polymorphisms are associated with PsA. The activating KIRs KIR2DS1 and KIR2DS2 have been associated with PsA, particularly in the absence of the HLA ligands for the corresponding inhibitory KIRs (KIR2DL1 and KIR2DL2/3) [1315]. Furthermore, it was shown that the susceptibility to PsA may be determined by the overall balance of activating and inhibitory composite KIR-HLA genotypes [13] . These studies have analysed KIR2D polymorphisms only, because of the known association of their recognized ligand HLA-C alleles with psoriasis (and PsA). However, PsA is more strongly associated with HLA-B alleles that interact with KIR3D. We therefore conducted a casecontrol study using a large number of well-phenotyped subjects to determine the association between KIR2D and KIR3D gene polymorphisms and their interaction with HLA alleles in PsA.
Methods

Subjects
Subjects were selected from the University of Toronto PsA program database. As described previously, 678 PsA cases satisfying the Classification Criteria for Psoriatic Arthritis (CASPAR) and 688 healthy controls were selected for the current study [16] . A cohort of 369 patients with chronic plaque psoriasis who were examined by a rheumatologist to exclude PsA (PsC) were also included as disease controls. All patients and controls were Caucasian. Ethical approval for this study was obtained from the University Health Network Research Ethics Board. All participants in this study gave the appropriate written informed consent for their participation.
Genotyping DNA was extracted from peripheral blood using a modified salting out procedure (Gentra Puregene Blood Kit, QIAGEN). KIR typing was performed by PCR amplification with sequence-specific primers (PCR-SSP) for each gene based on sequencing data. Commercial primers (Invitrogen KIR Genotyping SSP kits) were used for typing 15 informative KIR polymorphisms (2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1) [6] . Proficiency in KIR genotype assignment was assured through participation in the KIR International DNA exchange program administered through the University of California at Los Angeles Immunogenetics Center. The results were reported as the presence/absence for each of the individual KIR genotypes. HLA typing was performed as described previously [16] .
Statistical analysis
Frequency differences between cases and healthy controls in the presence of individual KIR polymorphisms were tested for significance by an asymptotic 2 test and Fisher's exact test. The risk of PsA associated with the presence of a KIR polymorphism was estimated by the odds ratios (ORs) and corresponding 95% CIs.
Since associations between KIR2DS polymorphisms and PsA have been previously described, the threshold for statistical significance was set at P < 0.05 [1315] . Subsequently, stepwise multivariate logistic regression analysis was conducted to identify KIR polymorphisms independently associated with PsA compared with healthy controls. KIR polymorphisms were included if they were significant at the 5% level in univariate analyses or had been reported to be associated in previous KIR association studies in PsA (KIR2DS1, 2DS2).
Associations were retained in the multivariate regression if the P-value from the two-sided Wald test was <0.05, and corresponding ORs and large sample 95% CIs were obtained. Associations found to be significant when comparing PsA with controls were then investigated between PsC and controls, as well as between PsA and PsC to determine whether the associations found were specific to PsA. Trends for increasing susceptibility to PsA compared with healthy controls from combined genotypes (HLA-KIR and HLA) were evaluated by the CochranArmitage trend test, with ORs and large sample 95% CIs obtained by logistic regression. All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The demographic and disease characteristics of the PsA and PsC patients included in this study are provided in Table 1 . All patients with PsA satisfied the CASPAR criteria and those with PsC were diagnosed by a dermatologist and were evaluated by a rheumatologist to exclude PsA. The results of univariate analyses comparing PsA with healthy controls (Table 2) show that only KIR2DL2 and KIR2DS2 are significantly associated with a higher risk of PsA compared with controls. The previously reported gene KIR2DS1 only showed a minor trend towards association (P = 0.167). Multivariate logistic regression analysis performed to identify KIR polymorphisms independently associated with PsA included KIR2DL2, KIR2DS2 (both P < 0.05 in univariate analysis) and KIR2DS1 (previously reported). Only KIR2DS2 was independently associated with PsA (OR 1.25, 95% CI 1.01, 1.54, P = 0.044).
When comparing PsC with controls, no association of KIR2DL2 (P = 0.55), KIR2DS1 (P = 0.24) and KIR2DS2 (P = 0.63) with PsC could be demonstrated. However, when comparing PsA with PsC, KIR2DS2 was significantly associated with PsA (OR 1.34, 95% CI 1.04, 1.73, P = 0.024). Thus the association between KIR2DS2 and PsA is likely to be specific to arthritis.
Subsequently the association between PsA and combined HLA and HLA-KIR genotypes was examined. HLA-C alleles may be classified into HLA-C group 1 or group 2: group 1 alleles are recognized by KIR2DL2/KIR2DS2 and group 2 alleles are recognized by KIR2DL1/KIR2DS1. Each subject can have zero, one or two HLA-C group 1 or group 2 alleles. The presence of HLA-C group 2 was associated with a higher risk of PsA (trend test P = 0.006). The OR for PsA given the presence of one or two group 2 alleles was 1.26 (95% CI 1.00, 1.59, P = 0.048) or 1.53 (95% CI 1.10, 2.13, P = 0.012), respectively, compared with having no group 2 alleles (reference group).
NK and NK-T cells are activated by KIR2DS receptors, especially if the corresponding inhibitory KIR2DL receptor and/or their HLA class I ligands are not present. Given the nature of this biological interaction between KIR2DS2 and HLA-C group 1, a hierarchy of risk for disease was constructed. When examining KIR2DS2, the risk is expected to be lowest if KIR2DS2 is absent (combination 1), intermediate if KIR2DS2 as well as KIR2DL2/2DL3 and HLA-C group 1 are present (combination 2), and highest if KIR2DS2 is present along with KIR2DL2/2DL3 in the absence of HLA-C group 1 or if KIR2DS2 is present without KIR2DL2/2DL3 (combination 3) (trend test P = 0.027; Table  3 ). The ORs for PsA given the presence of combination 3 and combination 2 were 1.42 (95% CI 0.93, 2.17, P = 0.101) and 1.23 (95% CI 0.99, 1.54, P = 0.063), respectively, compared with having combination 1 (reference group). Using a logistic model, no statistically significant interaction between the presence of KIR2DS2 and HLA-C group 1 could be demonstrated. A similar analysis for KIRD2DS1 and HLA-C group 2 did not show evidence of an association (trend test P = 0.90; Table 4 ).
Given the epidemiological relationship between PsA and HIV disease, we sought to determine the association between HLA-C high alleles (HLA-C*02, *05, *06, *08, *12, *15, *16) and PsA and whether there was an interaction with KIR2DS. Each subject can have zero, one or two HLA-C high alleles. The presence of HLA-C high alleles was associated with a higher risk of PsA (trend test P < 0.0001). The ORs for PsA given the presence of one and two HLA-C high alleles were 1.53 (95% CI 1.20, 1.95, P = 0.001) and 2.65 (95% CI 1.93, 3.66, P < 0.001), respectively, compared with having no HLA-C high alleles (reference group). The association with HLA-C high remained even after adjusting for HLA-C*06 in a logistic model. Subsequently we examined the interaction between KIR2DS and HLA-C high. For the purpose of this analysis, patients were classified as KIR2DS present if they had either KIR2DS1 or KIR2DS2 present, otherwise they were classified as KIR2DS absent. No evidence of a statistical interaction between HLA-C high and KIR2DS could be demonstrated.
HLA-B alleles may be classified into two groups depending on whether the allele carries the Bw4 or Bw6 motif (herein referred to as HLA-B Bw4 and Bw6 alleles). Each subject can have zero, one or two HLA-B Bw4 alleles. The presence of HLA-B Bw4 was associated with higher risk of PsA (trend test P < 0.001) compared with controls. The ORs for PsA given the presence of one and two Bw4 alleles were 1.60 (95% CI 1.26, 2.04, P = 0.001) and 2.56 (95% CI 1.85, 3.54, P < 0.001), respectively, compared with having no Bw4 alleles (reference group). Further, HLA-B Bw4 alleles may be further classified into Bw4 80ile and Bw4 80thr alleles. HLA-B Bw4 80ile interacts epistatically with KIR3DS1 [10] . Each subject can have zero, one or two HLA-B Bw4 80ile alleles. The presence of HLA-B Bw4 80ile was associated with a higher risk of PsA (trend test P < 0.001). The ORs for PsA given the presence of one and two Bw4 80ile alleles were 1.67 (95% CI 1.32, 2.12, P < 0.001) and 2.13 (95% CI 1.16, 3.92, P = 0.015), respectively, compared with having no Bw4 80ile alleles (reference group). Subsequently, interaction between KIR3DS1 and HLA-B Bw4 80ile was examined, but no evidence of a statistical interaction between KIR3DS1 and HLA-B Bw4 80ile could be demonstrated.
Discussion
The association between alleles of HLA class I molecules and PsA indicates a potential role for the innate immune system in PsA pathogenesis [1] . NK cells form a part of the innate immune system and play an important role in clearing malignant and virus-infected cells [5] . NK cells have been implicated in primary or secondary pathogenic responses in PsA. These cells have been found in the synovial fluid of inflamed joints of PsA patients, and there is evidence that synovial cells of PsA patients can induce monocytic differentiation into dendritic cells in an NK celldependent manner [3, 4, 17] . The response of NK cells to target cells is dependent on the balance of signals transmitted through inhibitory and activating NK receptors (NKRs). In humans, NKRs can be divided into three classes: the Ig-like receptors, including KIRs and leucocyte Ig-like receptors (LIRs or LILRs), the lectin-like receptors (CD94/ NKG) and the natural cytotoxicity receptors (NCRs), including NKp30, NKp44 and NKp46 [5] . The KIRs are a group of highly polymorphic inhibitory and activating NKRs that recognize classical MHC class I HLA molecules [18] . PsA is associated with HLA-B and -C alleles that biologically interact with KIR3D and KIR2D receptors, respectively. Using a well-characterized cohort of patients with PsA and healthy controls, we showed that KIR2DS2 is independently associated with PsA. The association is specific to PsA and not psoriasis alone (PsC). The presence of HLA C group 2 alleles is associated with a higher risk of PsA compared with controls. We also showed that the risk of PsA is higher when KIR2DS2 is present with the HLA-C ligands (group 1) for the corresponding inhibitory KIRs, and is highest when KIR2DS2 is present in the absence of HLA-C ligands for homologous inhibitor KIRs compared with the state when KIR2DS2 is absent. The presence of HLA-C alleles that have high cell surface expression is also associated with an increased risk of PsA. Although the association between HLA-B Bw4 and HLA-B Bw4 80ile is associated with a higher PsA risk, no interaction between HLA-B Bw4 80ile and KIR3DS1 could be demonstrated.
Activating KIRs have previously been shown to be associated with PsA [14, 15] . The association has primarily been with KIR2DS1. The largest study showed that KIR2DS1 and/or KIR2DS2 are markers for PsA, but only when HLA ligands for their homologous inhibitory receptors, KIR2DL1 and KIR2DL2/3, are absent [14] . In the present study, which is the largest to date with well-phenotyped subjects, KIR2DS2 was found to have the most important risk association among the KIR polymorphisms. The study also confirmed that PsA is associated with the absence of the ligands for the corresponding inhibitory KIR2DL2. KIR2DS2 has been shown to be associated with a number of inflammatory diseases, including systemic sclerosis, SS and vascular events in SLE [1922] . Association studies in psoriasis have reported a primary association with KIR2DS1 and not with KIR2DS2 [23, 24] . Most studies done to date have been small and relatively underpowered.
Studies to date in psoriasis and PsA have investigated KIR2DS because these genes are known to interact with HLA-C, the strongest risk factor for psoriasis. However, PsA has a stronger association with HLA-B alleles than with HLA-C. Therefore we investigated the relationship of HLA-Bw4 and Bw6 alleles as well as KIR3DS with PsA. In AS, a disease strongly associated with HLA-B*27 and closely related to PsA, KIR3DS1 is associated with AS compared with HLA-B*27-positive controls in Caucasian populations from Spain and the Azores [25] . The association of KIR3DS1 with AS was found in combination with HLA-B Bw4 80ile alleles. However, a subsequent study from the UK did not find an association [26] . In a more recent study from Spain in which KIR3DS1 and KIR3DL1 alleles were genotyped by sequence-specific oligonucleotide probes, a higher frequency of the KIR3DS1*013 allele in patients with AS was found 
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KIR genes in PsA independent of the presence of the HLA-B Bw4 80ile epitope, whereas the presence of inhibitory allotypes such as KIR3DL1*004 demonstrated a negative association in the presence of HLA-B Bw4 80ile [27] . In the present study in PsA, HLA-B Bw4 and HLA-B Bw4 80ile were associated with a higher PsA risk, but no interaction between HLA-B Bw4 80ile and KIR3DS1 could be demonstrated. An interesting observation was the higher risk of PsA associated with HLA-C alleles that lead to high HLA-C cell surface expression. The association remained even after adjusting for HLA-C*06, the most important psoriasis risk allele. It was shown recently that individuals with highexpressing HLA-C alleles progress more slowly to AIDS and control viraemia significantly better than individuals with low HLA-C-expressing alleles, probably through better antigen presentation to cytotoxic T lymphocytes or recognition and killing of infected cells by NK cells [7] . A more recent study confirmed this observation in HIV, and confirmed as well that HLA-B*57, B*27, B*14/C*08, B*52 and A*25 (all except B*14 are Bw4 alleles) are associated with better HIV control and that B*35 (Bw6 allele) and C*07 (low cell surface expression) are alleles that are associated with HIV progression [28] . Compared with healthy controls, we have shown that HLA-C high alleles as well as HLA-B*57 and B*27 are associated with a higher risk of PsA, and HLA-C*07 is associated with a lower risk [16] . Thus these observations suggest that individuals with risk alleles probably have an inflammatory milieu that leads to better HIV control, which leads to a higher risk for PsA, and vice versa. These shared genetic risk factors may explain the epidemiological association observed between HIV disease and SpA/ psoriasis.
To conclude, this large casecontrol study in a welldefined population has confirmed the association between PsA and KIR2DS genes, especially KIR2DS2. A higher risk conferred by HLA-B Bw4 alleles and by HLA-C alleles that have high cell surface expression was demonstrated. These results indicate a potential role for NK cells in PsA pathogenesis because KIRs interact with these alleles to enhance the inflammatory response. It should be noted, however, that NK cell regulation depends on the overall balance of activating/ inhibitory receptors and their ligands. It is therefore difficult to demonstrate interactions between one KIR polymorphism and its ligand at a time in PsA. Further studies will require genotyping to determine KIR allele associations as well as replication in an independent population.
Rheumatology key messages
. The activating KIR gene KIR2DS2 is specifically associated with susceptibility to PsA. . There is statistical interaction between KIR2DS2
and HLA class I alleles in PsA susceptibility. . Natural killer cells may play a role in the pathogenesis of PsA.
